Erluo Chen
Merck & Co., Inc., Rahway, NJ, USA (United States) · 60 works · 9,600 citations · h-index 30
Top works
- A Prospective Study of Venous Thromboembolism after Major Trauma
- Measured Enthusiasm: Does the Method of Reporting Trial Results Alter Perceptions of Therapeutic Effectiveness?
- Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes
- A Comparison of Low-Dose Heparin with Low-Molecular-Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma
- Use of Cardiac Procedures and Outcomes in Elderly Patients with Myocardial Infarction in the United States and Canada
- Prevalence of Vitamin D Inadequacy among Postmenopausal North American Women Receiving Osteoporosis Therapy
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- Population-wide mortality trends among patients hospitalized for acute myocardial infarction: The Ontario experience, 1981 to 1991
- Selective Screening for Gestational Diabetes Mellitus
- Prevalence of Vitamin D Inadequacy Among Postmenopausal North American Women Receiving Osteoporosis Therapy
- Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study
- A randomized study of the systemic effects of warm heart surgery
- Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
- Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial
- Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis
- Comparison of Weekly Treatment of Postmenopausal Osteoporosis with AlendronateVersusRisedronate Over Two Years
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
- Variation in Hospital Length of Stay for Acute Myocardial Infarction in Ontario, Canada
- Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
- Self-perceived health status of women three to five years after the diagnosis of gestational diabetes: A survey of cases and matched controls